Assessing the validity of a self-reported clinical diagnosis of schizophrenia.
Journal
Schizophrenia (Heidelberg, Germany)
ISSN: 2754-6993
Titre abrégé: Schizophrenia (Heidelb)
Pays: Germany
ID NLM: 9918367987006676
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
23
05
2024
accepted:
15
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
The increasing availability of biobanks is changing the way individuals are identified for genomic research. This study assesses the validity of a self-reported clinical diagnosis of schizophrenia. The study included 1744 clinically-ascertained participants with schizophrenia or schizoaffective disorder depressed-type (SA-D) diagnosed by self-report and/or research interview and 1453 UK Biobank participants with self-reported and/or medical record diagnosis of schizophrenia or SA-D. Unaffected controls included a total of 501,837 participants. We assessed the positive predictive values (PPV) of self-reported clinical diagnoses against research interview and medical record diagnoses. Polygenic risk scores (PRS) and phenotypes relating to demographics, education and employment were compared across diagnostic groups. The variance explained (r
Identifiants
pubmed: 39477999
doi: 10.1038/s41537-024-00526-5
pii: 10.1038/s41537-024-00526-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
99Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : U/01MH109514
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : U01MH109514
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : Award U01MH109514
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/P005748/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/P005748/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/P005748/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/W014386/1
Informations de copyright
© 2024. The Author(s).
Références
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013.
World Health Organisation. Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia . Published 2022. Accessed 20th December 2022.
Harvey, P. D. et al. Diagnosis of schizophrenia: consistency across information sources and stability of the condition. Schizophr. Res. 140, 9–14 (2012).
pubmed: 22503641
pmcid: 3399919
doi: 10.1016/j.schres.2012.03.026
Haapea, M. et al. Non-participation may bias the results of a psychiatric survey. Soc. Psychiatry Psychiatr. Epidemiol. 42, 403–409 (2007).
pubmed: 17404677
doi: 10.1007/s00127-007-0178-z
Reinikainen, J. et al. Participation rates by educational levels have diverged during 25 years in Finnish health examination surveys. Eur. J. Public Health 28, 237–243 (2017).
doi: 10.1093/eurpub/ckx151
O’Connell, K. S. et al. Genomics yields biological and phenotypic insights into bipolar disorder. Preprint at https://www.medrxiv.org/content/10.1101/2023.10.07.23296687v3 (2024).
Weiser, M. et al. Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-L. Compr. Psychiatry. 46, 38–42 (2005).
pubmed: 15714193
pmcid: 3089940
doi: 10.1016/j.comppsych.2004.07.016
Williams, J., Farmer, A., Ackenheil, M., Kaufmann, C. & McGuffin, P. Group ORR. A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol. Med. 26, 775–783 (1996).
pubmed: 8817712
doi: 10.1017/S003329170003779X
Vares, M., Ekholm, A., Sedvall, G. C., Hall, H. & Jönsson, E. G. Characterization of patients with schizophrenia and related psychoses: evaluation of different diagnostic procedures. Psychopathology 39, 286–295 (2006).
pubmed: 16960467
doi: 10.1159/000095733
Ekholm, B. et al. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord. J. psychiatry 59, 457–464 (2005).
pubmed: 16316898
doi: 10.1080/08039480500360906
Davis, K. A., Sudlow, C. L. & Hotopf, M. Can mental health diagnoses in administrative data be used for research? A systematic review of the accuracy of routinely collected diagnoses. BMC Psychiatry 16, 1–11 (2016).
doi: 10.1186/s12888-016-0963-x
Pasman, J. A. et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nat. Neurosci. 21, 1161–1170 (2018).
pubmed: 30150663
pmcid: 6386176
doi: 10.1038/s41593-018-0206-1
Wray, N. R. et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat. Genet. 50, 668–681 (2018).
pubmed: 29700475
pmcid: 5934326
doi: 10.1038/s41588-018-0090-3
Demontis D., et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat. Genet. 51:63 (2019).
Dalby, M. et al. Characterizing mood disorders in the AFFECT study: a large, longitudinal, and phenotypically rich genetic cohort in the US. Transl. Psychiatry 12, 121 (2022).
pubmed: 35338122
pmcid: 8956583
doi: 10.1038/s41398-022-01877-2
Levey, D. F. et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat. Neurosci. 24, 954–963 (2021).
pubmed: 34045744
pmcid: 8404304
doi: 10.1038/s41593-021-00860-2
Hyde, C. L. et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat. Genet. 48, 1031–1036 (2016).
pubmed: 27479909
pmcid: 5706769
doi: 10.1038/ng.3623
Davis, K. A. et al. Indicators of mental disorders in UK Biobank—A comparison of approaches. Int. J. Methods Psychiatr. Res. 28, e1796 (2019).
pubmed: 31397039
pmcid: 6877131
doi: 10.1002/mpr.1796
Mallard, T. T. et al. Multivariate GWAS of psychiatric disorders and their cardinal symptoms reveal two dimensions of cross-cutting genetic liabilities. Cell Genom. 2, 100140 (2022).
pubmed: 35812988
pmcid: 9264403
doi: 10.1016/j.xgen.2022.100140
Wainberg, M., Jacobs, G. R., di Forti, M. & Tripathy, S. J. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Transl. Psychiatry 11, 211 (2021).
pubmed: 33837184
pmcid: 8035271
doi: 10.1038/s41398-021-01330-w
Jermy, B. S., Hagenaars, S., Coleman, J. R., Vassos, E. & Lewis, C. M. Risk factor profiles for depression following childbirth or a chronic disease diagnosis: case–control study. BJPsych Open. 8, e182 (2022).
pubmed: 36205003
pmcid: 9634597
doi: 10.1192/bjo.2022.586
Levey, D. F. et al. Reproducible Genetic Risk Loci for Anxiety: Results From similar to 200,000 Participants in the Million Veteran Program. Am. J. Psychiatry 177, 223–232 (2020).
pubmed: 31906708
pmcid: 7869502
doi: 10.1176/appi.ajp.2019.19030256
Cai, N. et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nat. Genet. 52:437 (2020).
Waszczuk, M. A. et al. Dimensional and transdiagnostic phenotypes in psychiatric genome-wide association studies. Mol. Psychiatry 28, 4943–4953 (2023).
pubmed: 37402851
pmcid: 10764644
doi: 10.1038/s41380-023-02142-8
Liu, H. et al. Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX. Alzheimer’s. Res. Ther. 14, 17 (2022).
doi: 10.1186/s13195-022-00963-3
Schoeler, T., Pingault, J.-B. & Kutalik, Z. Self-report inaccuracy in the UK Biobank: Impact on inference and interplay with selective participation. Preprint at https://www.medrxiv.org/content/10.1101/2023.10.06.23296652v1 (2023).
Zheutlin, A. B. et al. Penetrance and Pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four health care systems. Am. J. Psychiatry 176, 846–855 (2019).
pubmed: 31416338
pmcid: 6961974
doi: 10.1176/appi.ajp.2019.18091085
Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604, 502–508 (2022).
pubmed: 35396580
pmcid: 9392466
doi: 10.1038/s41586-022-04434-5
Underwood, J. F. G. et al. Autism spectrum disorder diagnosis in adults: phenotype and genotype findings from a clinically derived cohort. Br. J. Psychiatry 215, 647–653 (2019).
pubmed: 30806336
pmcid: 6949119
doi: 10.1192/bjp.2019.30
Wing, J. K. et al. SCAN: Schedules for clinical assessment in neuropsychiatry. Arch. Gen. Psychiatry 47, 589–593 (1990).
pubmed: 2190539
doi: 10.1001/archpsyc.1990.01810180089012
Legge, S. E. et al. Clinical indicators of treatment-resistant psychosis. Br. J. Psychiatry 216, 259–266 (2020).
pubmed: 31155017
doi: 10.1192/bjp.2019.120
Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
pubmed: 25826379
pmcid: 4380465
doi: 10.1371/journal.pmed.1001779
Dennison, C. A. et al. Risk factors, clinical features, and polygenic risk scores in schizophrenia and schizoaffective disorder depressive-type. Schizophr. Bull. 47, 1375–1384 (2021).
pubmed: 33837784
pmcid: 8379553
doi: 10.1093/schbul/sbab036
Escott-Price, V. et al. Genetic liability to schizophrenia is negatively associated with educational attainment in UK Biobank. Mol. Psychiatry 25, 703–705 (2020).
pubmed: 30610204
doi: 10.1038/s41380-018-0328-6
McCarthy, S., Das, S. & Kretzschmar, W. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).
pubmed: 27548312
pmcid: 5388176
doi: 10.1038/ng.3643
Lynham, A. J. et al. DRAGON-Data: a platform and protocol for integrating genomic and phenotypic data across large psychiatric cohorts. BJPsych Open. 9, e32 (2023).
pubmed: 36752340
pmcid: 9970169
doi: 10.1192/bjo.2022.636
The 1000 Genomes Project Consortium, Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
doi: 10.1038/nature15393
Chang C. C., et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:s13742-13015-10047-13748.
Leonenko, G. et al. Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores. Nat. Commun. 12, 1–10 (2021).
doi: 10.1038/s41467-021-24082-z
Conomos, M. P. et al. Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am. J. Hum. Genet. 98, 165–184 (2016).
pubmed: 26748518
pmcid: 4716704
doi: 10.1016/j.ajhg.2015.12.001
Bycroft, C. et al. Genome-wide genetic data on ~ 500,000 UK Biobank participants. Preprint at https://www.biorxiv.org/content/10.1101/166298v1 (2017).
Legge, S. E. et al. Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. JAMA Psychiatry 76, 1256–1265 (2019).
pubmed: 31553412
pmcid: 6764002
doi: 10.1001/jamapsychiatry.2019.2508
Choi, S. W. O’Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience 8, giz082 (2019).
pubmed: 31307061
pmcid: 6629542
doi: 10.1093/gigascience/giz082
Stahl, E. A. et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat. Genet. 51, 793–803 (2019).
pubmed: 31043756
pmcid: 6956732
doi: 10.1038/s41588-019-0397-8
Tenny S., Hoffman M. R. Prevalence. In: StatPearls. Treasure Island (FL) StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
Davies, M. R. et al. Comparison of symptom-based versus self-reported diagnostic measures of anxiety and depression disorders in the GLAD and COPING cohorts. J. Anxiety Disord. 85, 102491 (2022).
pubmed: 34775166
doi: 10.1016/j.janxdis.2021.102491
Vieira, L. S. et al. Self-reporting of psychiatric illness in an online patient registry is a good indicator of the existence of psychiatric illness. J. Psychiatr. Res. 151, 34–41 (2022).
doi: 10.1016/j.jpsychires.2022.03.022
Mitchell, A. J. Reluctance to disclose difficult diagnoses: a narrative review comparing communication by psychiatrists and oncologists. Support. Care Cancer 15, 819–828 (2007).
pubmed: 17333297
doi: 10.1007/s00520-007-0226-y
Paccaloni, M., Moretti, F. & Zimmermann, C. Giving information and involving in treatment: what do psychiatrists think? A review. Epidemiol. Psychiatr. Sci. 14, 198–216 (2005).
doi: 10.1017/S1121189X00007958
Clafferty, R. A., McCabe, E. & Brown, K. W. Conspiracy of silence? Telling patients with schizophrenia their diagnosis. Psychiatr. Bull. 25, 336–339 (2001).
doi: 10.1192/pb.25.9.336
Meier, S. M. et al. High loading of polygenic risk in cases with chronic schizophrenia. Mol. Psychiatry 21, 969–974 (2016).
pubmed: 26324100
doi: 10.1038/mp.2015.130
Glanville, K. P. et al. Multiple measures of depression to enhance validity of major depressive disorder in the UK Biobank. BJPsych Open. 7, e44 (2021).
pubmed: 33541459
pmcid: 8058908
doi: 10.1192/bjo.2020.145
Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017).
pubmed: 28641372
pmcid: 5860371
doi: 10.1093/aje/kwx246